- Home
- AXIL vs PTN Comparison
AXIL vs PTN Comparison
Compare AXIL & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- PTN
- Stock Information
- Founded
- AXIL 2015
- PTN 1986
- Country
- AXIL United States
- PTN United States
- Employees
- AXIL N/A
- PTN N/A
- Industry
- AXIL Package Goods/Cosmetics
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- AXIL Consumer Discretionary
- PTN Health Care
- Exchange
- AXIL Nasdaq
- PTN Nasdaq
- Market Cap
- AXIL 25.6M
- PTN 25.4M
- IPO Year
- AXIL N/A
- PTN 1993
- Fundamental
- Price
- AXIL $4.38
- PTN $1.06
- Analyst Decision
- AXIL
- PTN Strong Buy
- Analyst Count
- AXIL 0
- PTN 1
- Target Price
- AXIL N/A
- PTN $17.00
- AVG Volume (30 Days)
- AXIL 5.5K
- PTN 570.9K
- Earning Date
- AXIL 01-08-2025
- PTN 02-13-2025
- Dividend Yield
- AXIL N/A
- PTN N/A
- EPS Growth
- AXIL 135.54
- PTN N/A
- EPS
- AXIL 0.25
- PTN N/A
- Revenue
- AXIL $26,554,439.00
- PTN $2,384,113.00
- Revenue This Year
- AXIL N/A
- PTN N/A
- Revenue Next Year
- AXIL N/A
- PTN N/A
- P/E Ratio
- AXIL $17.32
- PTN N/A
- Revenue Growth
- AXIL N/A
- PTN N/A
- 52 Week Low
- AXIL $3.54
- PTN $0.68
- 52 Week High
- AXIL $14.00
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- AXIL 61.89
- PTN 47.60
- Support Level
- AXIL $3.97
- PTN $1.06
- Resistance Level
- AXIL $4.00
- PTN $1.20
- Average True Range (ATR)
- AXIL 0.15
- PTN 0.14
- MACD
- AXIL 0.04
- PTN -0.01
- Stochastic Oscillator
- AXIL 91.97
- PTN 7.14
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.